Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment Policymedical mutual - ohio Eliquis Prior Auth Coverage …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Recommended authorization criteria for Eliquis (apixaban) products

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Recommended authorization criteria for pharmacy benefit coverage of Eliquis (apixaban) products, including tablets, tablets for oral suspension, and Eliquis Sprinkle; applies to requests for coverage and prior authorization determinations by Medical Mutual - Ohio.

    Policy Summary
    Payermedical mutual - ohio
    PolicyRecommended authorization criteria for Eliquis (apixaban) products
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateNov 20, 2025
    Last ReviewNov 20, 2025
    Next Review DateNov 20, 2025
    Key ActionPrior authorization is recommended for pharmacy benefit coverage of Eliquis; approvals are provided when the specified criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearAF & treatment duration
    60 daysPost-op prophylaxis
    6 monthsOther thromboembolic
    weight bandsPediatric dosing noted

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Recommended Authorization Criteria

    Recommended authorization criteria by indication

    Coverage is recommended for Eliquis products when the indication-specific criteria (age/weight and prior-therapy requirements) below are met. Approval durations are shown per indication.

    Atrial Fibrillation, Nonvalvular (or Atrial Flutter): Approve for 1 year if the patient is ≥ 18 years of age.
    Deep Vein Thrombosis (DVT) Prophylaxis in Patients Undergoing Hip or Knee Replacement: Approve for 60 days if the patient is ≥ 18 years of age.
    Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), Treatment (Adults): Approve for 1 year if the patient weighs ≥ 35 kg.
    Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) to Reduce the Risk of Recurrence (Adults): Approve for 1 year if the patient weighs ≥ 35 kg.

    ALL of the following

    • Treatment or Prevention of Other Thromboembolic-Related Conditions (patients ≥ 35 kg): Approve for 6 months if criteria A and B are met.
    • A: Patient is ≥ 35 kg.
    • B - ONE of

      • Patient has tried warfarin, fondaparinux injection, or a low molecular weight heparin (LMWH) product (e.g., enoxaparin, dalteparin).
      • Patient has been started on Eliquis tablets for the treatment of an acute thromboembolic condition.
      • Exception: A patient who has tried rivaroxaban (Xarelto), dabigatran (Pradaxa), or edoxaban (Savaysa) is not required to trial warfarin, fondaparinux, or LMWH before approval.

    ALL of the following

    • Venous thromboembolic events — Treatment (patients < 35 kg) using Eliquis tablets for oral suspension or Eliquis Sprinkle: Approve for 1 year if patient weighs < 35 kg.
    • Venous thromboembolic events — To Reduce the Risk of Recurrence (patients < 35 kg) using Eliquis tablets for oral suspension or Eliquis Sprinkle: Approve for 1 year if patient weighs < 35 kg.

    Automation and Coding Rules

    Automation ICD-10 examplesICD-10
    I48.*Atrial fibrillation and flutter (used for automation)
    I82*Other venous embolism and thrombosis (used for automation)
    I27.82Chronic pulmonary embolism (used for automation)
    Z96.6*Presence of cardiac valve prosthesis (used for automation)
    inv-03: age requirement for automation
    Automation age requirement18 years or older for specified ICD-10 automation rules (e.g., I48.*, I82*, I27.82)
    Applies toEliquis tablets approvals when automation is available
    Source restrictionAutomation uses listed ICD-10 codes only as specified in policy
    inv-04: claim-history automation rule
    Z96.6* claim-history ruleAutomation requires the member be 18 years or older AND have not had 2 claims for the same medication within the last 180 days
    ScopeApplies when automation is used for approvals involving Z96.6*

    Prior Authorization and Documentation

    Prior Authorization

    Prior authorization required; automation uses specified ICD-10 and age/claim rules

    Prior authorization is recommended for pharmacy benefit coverage of Eliquis; approvals are provided when the conditions in the criteria and initial/extended approval are met. When available, automation uses the listed ICD-10 codes and age/claim-history rules to allow approval of Eliquis tablets.

    • Automation example codes for approval: I48.*; I82*; I27.82 with patient 18 years or older
    • Automation alternative: Z96.6* with patient 18 years or older and no 2 claims for the same medication within the last 180 days
    Documentation Required

    Provide documentation upon request or risk denial of reimbursement

    The Company reserves the right to request additional documentation as part of its coverage determination process and may deny reimbursement if the drug or services were not medically necessary, investigational/experimental, not within scope of benefits, or if a pattern of inappropriate or excessive billing/practice is found.

    Product Formulations and Age/Weight Bands

    inv-07: Eliquis Sprinkle (apixaban capsules for oral suspension) available as 0.15 mg for patients 2.6 to <4 kg
    Dosage form and strengthEliquis Sprinkle (apixaban capsules for oral suspension) available as 0.15 mg
    Pediatric weight bandFor patients 2.6 to <4 kg
    Study/label noteNot recommended for pediatric patients <2.6 kg because not studied
    inv-08: Eliquis tablets for oral suspension available as 0.5 mg for patients 4 to 35 kg
    Dosage form and strengthEliquis tablets for oral suspension available as 0.5 mg
    Pediatric weight bandFor patients 4 to 35 kg

    Initial Approval Criteria by Indication

    Initial approval

    Initial approvals are granted per indication when the criteria below are met. Durations shown reflect the initial approval period.

    Atrial fibrillation (nonvalvular): Patient ≥ 18 years — Approve for 1 year.
    DVT prophylaxis after hip or knee replacement: Patient ≥ 18 years — Approve for 60 days.
    DVT/PE treatment (adults): Patient ≥ 35 kg — Approve for 1 year.
    VTE recurrence reduction (adults): Patient ≥ 35 kg — Approve for 1 year.

    Continuation and Extended Approval

    Continuation therapy

    Reauthorization requires documented response to therapy unless otherwise noted; indication-specific durations apply.

    For all indications where continuation/extended approval is allowed, the prescriber must document clinical response to therapy at reauthorization unless otherwise specified in the indication criteria.

    Step Therapy Requirements

    StepRequirementFailure criteria / exceptionsApproval duration
    1Required trial of an alternative anticoagulant for certain 'other thromboembolic-related conditions'Patient has tried warfarin, fondaparinux injection, or a low molecular weight heparin (LMWH) product (e.g., enoxaparin, dalteparin). Note: patients who have tried rivaroxaban (Xarelto), dabigatran (Pradaxa), or edoxaban (Savaysa) are not required to try warfarin/fondaparinux/LMWH.6 months
    1Alternate path — patient already started on Eliquis for an acute thromboembolic conditionIf patient has been started on Eliquis for treatment of an acute thromboembolic condition, a prior trial of warfarin/fondaparinux/LMWH is not required.6 months
    1Weight-based distinction — patients ≥35 kgFor other thromboembolic-related conditions in patients ≥35 kg, the same trial requirement applies; patients started on Eliquis for an acute condition are excepted. (See failure criteria/exceptions above.)6 months
    1Other thromboembolic-related conditions in patients <35 kg (use of oral suspension or Sprinkle formulations)Patient has tried warfarin, fondaparinux, or LMWH OR has been started on Eliquis tablets for oral suspension or Eliquis Sprinkle for an acute thromboembolic condition.6 months
    Policy Summary
    Payermedical mutual - ohio
    PolicyRecommended authorization criteria for Eliquis (apixaban) products
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateNov 20, 2025
    Last ReviewNov 20, 2025
    Next Review DateNov 20, 2025
    Key ActionPrior authorization is recommended for pharmacy benefit coverage of Eliquis; approvals are provided when the specified criteria are met.
    SourceLink
    On This Page
    Recommended Authorization CriteriaAutomation and Coding RulesPrior Authorization and DocumentationProduct Formulations and Age/Weight BandsInitial Approval Criteria by IndicationContinuation and Extended ApprovalStep Therapy Requirements
    Interaction with other automation codesI48.*, I82*, I27.82 use age-only rule (18+); Z96.6* includes the additional claim-history requirement
    • Providers must make available upon request patient records, test results, and/or credentials of the provider ordering or performing a service to support medical necessity
    • The Company may modify, revise, change, apply and interpret this policy at its sole discretion
    Use note
    Different dosage forms can be used to achieve necessary pediatric dose; not all forms approved for same ages/indications
    inv-09: Eliquis tablets available as 2.5 mg and 5 mg for patients ≥ 35 kg
    Dosage form and strengthsEliquis tablets available as 2.5 mg and 5 mg
    Patient weight indicationFor use in patients ≥ 35 kg
    Formulation availabilityStandard tablet formulations remain available for appropriate indications and weight groups